PHAR Q1 2026 Earnings EPS Misses Estimates by Wide Margin Dave Busters PLAY Q1 2026 Earnings Massive EPS Miss on Estimated Loss But Stock Rises Amid Strategic Shifts MKC Q1 2026 Earnings Strong EPS Beat Amid Market Challenges Reviva Pharmaceuticals RVPH Q1 2026 Earnings NarrowerthanExpected Loss Highlights Cost Discipline Amid PreRevenue Stage JKS Q4 2025 Earnings Significant EPS Miss Despite Modest Share Gain CCAP Q1 2026 Earnings Narrow EPS Miss Highlights Steady Portfolio Returns